• Publications
  • Influence
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
TLDR
It is demonstrated that dabigatran etexilate is a highly cost-effective alternative to current care for the prevention of stroke and systemic embolism among Canadian AF patients.
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
TLDR
Dabigatran is economically dominant versus rivaroxaban for prevention of stroke and systemic embolism among Canadian AF patients and had high probability of being the most cost-effective therapy at common thresholds of willingness-to-pay.
The Cost-Effectiveness of Ibrutinib in Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
TLDR
It is demonstrated that ibrutinib is cost-effective and greatly improves long-term health outcomes over current treatments in this hard-to-treat population with very high unmet need.
A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
TLDR
Despite differences in model designs and structures, it was mostly possible to replicate the results published by different authors and identify variables responsible for differences between ICERs using a reference model approach.
Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
TLDR
Compared with EFV/TDF/FTC, DTG + ABC/3TC resulted in higher cost and only slightly increased QALYs over a lifetime, with an ICER that exceeded the standard cost-effectiveness threshold and indicates that the incremental benefit in effectiveness associated withDTG‬+‬3TC may not be worth the incremental increase in costs.
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries
TLDR
Dabigatran was found to dominate rivaroxaban in this study using US Medicare real-world data, and results may not be generalizable to other patient populations.
Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States.
TLDR
Screening using the 4th-generation assay may be cost-effective for HIV detection in appropriate settings, resulting in increased case identification, fewer transmissions, extended life, and increased quality of life.
...
1
2
3
...